PCAOB Enforcement Activity in 2023 Reached its Highest Level Since 2017 as Monetary Penalties Nearly Doubled Previous Record

John R. Hauser

Kirin Professor of Marketing,
MIT Sloan School of Management,
Massachusetts Institute of Technology

John Hauser is an expert in survey design, demand forecasting, product confusion, product feature valuation, and measurement of consumer preferences, beliefs, and willingness to pay. Professor Hauser has testified in more than seventy-five antitrust, consumer fraud, product liability, and intellectual property matters. His industry expertise includes consumer goods, entertainment, insurance, high tech, pharmaceuticals, and telecommunications.

In his research, Professor Hauser addresses issues of new product and service development, marketing management, and competitive strategy. He has applied sophisticated statistical and market research techniques, including machine learning and conjoint analyses, to examine consumer purchasing decisions.

Professor Hauser has coauthored two textbooks, Essentials of New Product Management and Design and Marketing of New Products; the latter ranked as one of the most-cited works in the Journal of Product Innovation over a twenty-year period. Professor Hauser was the editor of Marketing Science, departmental editor at Management Science, and associate editor at the Journal of Marketing Research.

Among his numerous honors, Professor Hauser received the Buck Weaver Award from the INFORMS Society for Marketing Science, which recognizes lifetime contributions to the theory and practice of marketing science. The American Marketing Association honored him with the Churchill Award and the Parlin Award, both for lifetime achievement in marketing research. He has been recognized with an honorary doctorate from the Erasmus School of Economics for his outstanding research contributions to the field of online marketing.

At MIT Sloan, Professor Hauser has served as research director of the Center for Innovation in Product Development, and codirector of the International Center for Research on the Management of Technology. He received an outstanding teaching award from the MIT Sloan School’s master’s program, where he teaches courses on marketing management and marketing innovation.

Darius Lakdawalla

Quintiles Chair in Pharmaceutical Development and Regulatory Innovation, School of Pharmacy,
Professor, Sol Price School of Public Policy,
Director of Research, Leonard D. Schaeffer Center for Health Policy and Economics,
University of Southern California

Darius Lakdawalla is a leading authority on health economics and health policy. Professor Lakdawalla has extensive expertise in pharmaceutical industry policy, medical innovation, prescription drug pricing and drug competition, as well as health insurance coverage and drug reimbursement by private payors and Medicare Part D. In connection with his research, Professor Lakdawalla has testified before Congress a number of times on topics related to innovation, patient access, and government reimbursement of prescription drugs including most recently in connection with the Inflation Reduction Act’s anticipated economic impacts on the pharmaceutical industry.

Professor Lakdawalla has been retained as an expert witness in multiple life sciences and healthcare matters, in which he evaluated both liability and damages issues. He has provided economic testimony related to allegations of product liability, breach of contract, misappropriation of trade secrets, product hopping, and generic drug price fixing. He also served as an expert for the merging parties in the Federal Trade Commission’s (FTC’s) challenge of Amgen’s acquisition of Horizon Therapeutics, addressing the FTC’s allegation that the acquisition would allow Amgen to entrench Horizon’s dominant position through the use of bundled rebates. Professor Lakdawalla has testified both in deposition and at trial.

Professor Lakdawalla also has extensive experience providing business consulting services to major pharmaceutical companies, as well as analyzing drug clinical trial data.

An award-winning researcher, Professor Lakdawalla has published articles in leading economics, medical, and health policy journals, including the American Economic Review, Health Affairs, the Quarterly Journal of Economics, the New England Journal of Medicine, and the Journal of the American Medical Association. His article “Economics of the Pharmaceutical Industry” was published in the Journal of Economic Literature. He has also coauthored chapters in the Handbook of Health Economics, The Oxford Handbook of the Economics of the Biopharmaceutical Industry, and The Elgar Companion to Health Economics (2nd edition), among others.

Professor Lakdawalla currently serves as an associate editor for the Journal of Health Economics. He was previously an associate editor for the American Journal of Health Economics and the Review of Economics and Statistics. He has also served as an expert panelist for the National Academy of Medicine. Professor Lakdawalla is a research associate at the National Bureau of Economic Research (NBER).

For more than a decade, Professor Lakdawalla has taught courses on health economics and policy, risk analysis, and health management. Before joining USC, he served as senior economist and director of research at the RAND Corporation’s Bing Center for Health Economics.

Lynda H. Schwartz

Professor of Practice,
Isenberg School of Management,
University of Massachusetts Amherst;
Former Partner, Fraud Investigation and Dispute Services,
Ernst & Young LLP

Lynda Schwartz is an expert in forensic accounting, data analytics, and damages, with a focus on fraud examination and risk assessment. Ms. Schwartz has more than thirty years of forensic accounting and auditing experience, analyzing economic, financial, causation, and accounting issues in the context of litigation claims and fraud allegations. Her work includes account reconstruction, lost profits, bankruptcy and business solvency, alleged embezzlement, and financial accounting. She has provided testimony at deposition, trial, and arbitration, as well as providing responses to regulators.

As a former partner in Ernst & Young’s Fraud Investigation and Dispute Services practice, Ms. Schwartz has led high-profile investigations involving regulatory compliance, whistleblowers, and allegations of fraud, corruption, and bribery. She has experience with discovery, complex financial modeling and data analytics, reconstruction of financial records, and damages calculations. Her industry expertise includes healthcare, insurance, manufacturing, financial services, and retail.

Ms. Schwartz is a Certified Public Accountant (CPA). She is also certified in financial forensics (CFF) and is both a Certified Fraud Examiner (CFE) and Certified Global Management Accountant (CGMA). She serves on the American Institute of Certified Public Accountants (AICPA) Joint Trial Board, which adjudicates certain matters of professional discipline. In 2021, the AICPA named Ms. Schwartz a Forensic & Litigation Services (FLS) Volunteer of the Year for her significant contributions to the practice and profession of forensic accounting and valuation.

At the Isenberg School of Management, Ms. Schwartz directs the forensic accounting and data analytics curriculum and teaches courses in forensic accounting and fraud examination. She has authored both practitioner and peer-reviewed publications. She served on the Update Task Force for the current edition of COSO’s Fraud Risk Management Guide. Ms. Schwartz is a contributing author to The Litigation Services Handbook (John Wiley & Sons) and to the AICPA publication Understanding the Forensic Technology Landscape.